1. Introduction {#sec1}
===============

A pheochromocytoma (PCC) is a rare catecholamine-secreting tumor that originates from the chromaffin cells of the adrenal medulla. First described by Frankel \[[@B1]\] in 1886, the estimated worldwide incidence of these tumors is 2 to 8 per million persons per year \[[@B2]\]. Classical symptoms at presentation include severe hypertension with associated headaches, sweating, and palpitations; however, 20--30% of patients remain asymptomatic. Asymptomatic PCCs are typically detected as an incidental adrenal mass on routine screening. Biochemical evidence of elevated plasma free metanephrines provides the highest sensitivity for PCC diagnosis \[[@B3]\]. Most of these lesions are benign/low metastatic potential but histopathological characteristics defined by the pheochromocytoma of the adrenal gland scaled score (PASS) can identify tumors with potentially more aggressive biological behavior such as the presence of chromaffin tissue at extra adrenal sites. Giant PCCs are generally classified as those with maximal diameter greater than 10 cm. They are commonly asymptomatic and are diagnosed incidentally on imaging. Surgical resection is the standard treatment option and is usually curative, preventing future potentially lethal complications of these lesions. We present the case of a 50-year-old female patient with a left side adrenal PCC which was treated successfully with open surgical resection in the surgical unit of Eric Williams Medical Sciences Complex, Trinidad and Tobago.

2. Case Presentation {#sec2}
====================

A 50-year-old East Indian woman with a 6-month history of lower back pain, fatigue, and unintentional weight loss was referred to our surgical outpatient clinic upon detection of a large abdominal mass during an abdominal ultrasound. The mass was located in the left upper quadrant and thought to be possibly splenic or renal in origin. Physical examination revealed a large nontender lump arising from the left upper quadrant and crossing the midline. Initial laboratory investigations were unremarkable except for microcytic anemia with a mean corpuscular hemoglobin concentration (MCHC) of 7.3 g/dL. The patient had no history of hypertension, headache, palpitations, or excessive sweating and no family history of cancer.

Computed tomography (CT) revealed a 23.2 × 17.6 × 13.6 cm mass with predominant areas of necrosis, punctate areas of calcification, and irregular contours superior to the left kidney (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). The mass displaced the pancreas anteriorly and compressed the left kidney inferiorly. The nonvisualization of a normal left adrenal gland strongly suggested an adrenocortical carcinoma. The liver, spleen, right adrenal gland, and right kidney were normal. Despite mesenteric and para-aortic lymphadenopathy there was no evidence of distant metastasis. Preoperative biopsy was not performed, due to the risk of tumor seeding along the biopsy path.

The tumor markers carcinoembryonic antigen, carbohydrate antigen (CA) 15-3, CA 19-9, and CA 125 were normal. The differential diagnosis included adrenocortical carcinoma, pheochromocytoma, myelolipoma, metastasis from an unidentified primary tumor, sarcoma, and lymphoma. Biochemical investigations were performed to exclude a functional adrenal mass, and the diagnosis of pheochromocytoma was made upon observation of elevated plasma free metanephrines, urine catecholamines, and their metabolites ([Table 1](#tab1){ref-type="table"}).

Preoperatively, the patient was transfused with packed red blood cells to stable hemoglobin of 10 g/dL. Adequate catecholamine blockade was achieved, after medical consultation using the alpha adrenergic blocker, terazosin (Hytrin). An open left adrenalectomy was performed through a Chevron incision extending to the left flank. The mass was completely resected en bloc with the spleen, distal pancreas, left kidney, and a 2 cm area of the left hemidiaphragm ([Figure 3](#fig3){ref-type="fig"}). Intraoperatively, there were significant fluctuations in the patient\'s blood pressure, which was well managed by the surgical team. There were no other significant surgical complications and the patient made an uneventful recovery prior to discharge on postoperative day 11. Three months later, at the time of this report, the patient remains stable and disease-free. Given that there is recurrence in approximately 10% of these cases, long-term follow-up with CT scans and hematologic monitoring is warranted.

Pathological examination of the surgical specimen revealed a circumscribed mass, surrounded by a variably thick fibrous capsule/pseudocapsule with relatively scantly attached fat, measuring 27 × 18 × 12 cm and weighing 3,315 g ([Figure 3](#fig3){ref-type="fig"}). Residual normal-appearing adrenal gland parenchyma was present, while neither infiltration of the surrounding fat, vascular invasion, nor confluent tumor necrosis was identified. Mitoses were rare (\<1 per high-power field). Histological sections revealed typical morphological features of PCC predominantly characterized by nests of plump tumor cells with abundant basophilic granular cytoplasm surrounded by sustentacular cells ([Figure 4(a)](#fig4){ref-type="fig"}). No unfavorable features such as diffuse growth pattern, increased cellularity, or increased pleomorphism were observed. The spleen, distal pancreas, and kidney did not show any pathologic abnormalities. Immunohistochemical staining revealed that the tumor cells were diffusely positive for chromogranin A ([Figure 4(b)](#fig4){ref-type="fig"}), while there was no significant highlighting of sustentacular cells by S-100. Of note, the lack of prominent staining of sustentacular cells by S-100 has been suggested to be predictive of nonfamilial sporadic PCC \[[@B4]\].

To determine the clinicopathological features of giant PCCs, an extensive literature search of the PubMed/MEDLINE and Embase databases was conducted. Search terms included "giant pheochromocytoma", "cystic giant pheochromocytoma", "English language" and "case reports". One case in which the tumor lacked dimensions but was found to be one of the heaviest PCCs recorded was included. Full texts were accessed to confirm eligibility for inclusion. A summary of the 36 final cases are presented in [Table 2](#tab2){ref-type="table"}. Relative to the others, our patient\'s tumor was the fourth heaviest with the fifth greatest maximal diameter and the largest histologically confirmed pheochromocytoma with a low risk of malignancy/benign classification. Unlike patients with classical symptoms, those with giant PCCs may be asymptomatic as occurred in 31% (=11) of the cases. Twenty-two % (=8) and 17% (=6) of the cases presented with hypertension and back/abdominal pain, respectively. Only one case had evidence of metastasis at the time of diagnosis, characterized by invasion of the right lobe of the liver \[[@B5]\]. Twenty-two percent (=8) of the cases presented at similar locations, commonly in the left abdomen. The mean age at diagnosis was 49.46 years (range 12--85 years) which was the age of our patient.

3. Discussion {#sec3}
=============

Pheochromocytomas are neoplasms that arise from the chromaffin cells of the sympathoadrenal system \[[@B6]\]. Eighty-five percent of these lesions arise in the adrenal medulla \[[@B7]\]. Sporadic cases of PCC usually present in the fourth to fifth decades of life. Various hereditary conditions such as multiple endocrine neoplasia 2A and 2B, Von Hippel-Lindau syndrome, and neurofibromatosis 1 are associated with increased risk for PCC \[[@B8]\]. There are no known environmental, dietary, or lifestyle risk factors that impact the risk of developing PCC. The classic tetrad of symptoms consists of palpitations, headaches, sweating, and hypertension. However, approximately 49--57% of PCC patients are asymptomatic with an adrenal mass being detected incidentally during unrelated imaging.

The malignant potential of a PCC cannot be determined preoperatively unless there is evidence of local invasion or metastases at the time of diagnosis. Previously, it was believed that size was a predictor of malignant potential; however, with numerous case reports of giant benign PCCs, size can no longer be used as a definitive indicator of aggressive disease \[[@B9]\]. Histologically, the PASS is referenced to distinguish tumors of high from those with a low risk of malignancy \[[@B10]\]. This scoring system assesses vascular invasion, capsular invasion, extension into the periadrenal adipose tissue, the presence of focal or confluent necrosis, high cellularity, tumor cell spindling, cellular monotony, \>3 mitoses per high-power field, atypical mitotic figures, profound nuclear pleomorphism, and increased tumor cell hyperchromasia \[[@B10]\]. Biologically aggressive tumors have been found to have a PASS ≥ 4 whereas lesions with a low risk of malignancy have a PASS \< 4. Our patient harbored a giant PCC with a low risk of malignancy as noted by the PASS of 2.

Approximately 20 to 30% of all PCCs are clinically silent \[[@B11]\]. Factors that contribute to the lack of symptoms include extensive necrosis of the adrenal gland, decreasing the production of catecholamines and the retention of these hormones within the capsular mass after secretion. Consequently, the time to diagnosis is delayed and tumor size tends to be larger once it is detected. A recent report that reviewed 20 cases of PCCs larger than 10 cm reported that 13 presented with abdominal pain with only 5 presenting with any of the classical symptoms of PCCs \[[@B12]\].

Surgical resection is the only curative option for these giant lesions. Laparoscopic adrenalectomy is considered safe and effective for tumors up to 12 cm in its greatest dimensions. However, in the realm of these giant PCCs, open en bloc resection is required. Intraoperative manipulation of these tumors is frequently associated with profound hypertension. However, early isolation of the tumor\'s venous drainage decreases the risk of intraoperative hypertensive crises \[[@B13]\]. This must be coupled with catecholamine blockade and intravenous fluids to diminish the risk of postoperative hypotension. It is therefore critical to have good coordination between the anesthesiologist and surgeon before and during surgery. Intensive care monitoring is crucial for at least 24 hours postoperatively as it is common for patients to experience fluctuations in blood pressure and heart rate as well as hypoglycemia. Pheochromocytomas have an excellent prognosis, with 5-year survival exceeding 95% in benign tumors and a recurrence rate of less than 10% \[[@B14]\]. Statistical data are not available for malignant PCCs due to their low incidence.

4. Conclusion {#sec4}
=============

In this report, we presented the case of a 50-year-old female with a giant PCC that was the fourth heaviest and had the fifth largest maximal diameter of all reported PCCs. Additionally, using our search criteria, the tumor had the largest maximal diameter of reported, histologically confirmed PCCs with a low risk of malignancy. Our patient, 3 months after resection of the tumor, remains stable and disease-free. Giant PCCs do not present with the classical symptoms associated with smaller PCCs and are usually associated with a lower risk of malignancy. Previously, larger size was believed to be an indicator of malignancy in these adrenal lesions; however, upon review of the 10 largest known PCCs, this belief was unsubstantiated.
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![CT scan showing a 23 cm, thick-walled, multicystic mass occupying most of the left upper quadrant of the abdomen.](CRIONM2017-4638608.001){#fig1}

![Coronal CT image demonstrating the mass displacing the left kidney inferiorly. Evidence of locally invasive disease was not present.](CRIONM2017-4638608.002){#fig2}

![En bloc resection of the left adrenal mass, pancreatic tail, spleen, and left kidney.](CRIONM2017-4638608.003){#fig3}

![Microscopic images of pheochromocytoma. (a) Routine hematoxylin and eosin (H&E) staining at low magnification (20x) highlights the typical "Zellballen" growth pattern characterized by nests of tumor cells surrounded by delicate fibrovascular stroma. (b) Immunohistochemistry for the neuroendocrine marker chromogranin A shows strong, diffuse staining in the tumor cells.](CRIONM2017-4638608.004){#fig4}

###### 

Biochemical investigations confirming the pheochromocytoma diagnosis.

                                  Patient values   Normal values
  ------------------------------- ---------------- --------------------
  *Test (fractionated plasma)*                      
  Metanephrine                    259 pg/mL        \<58 pg/mL
  Normetanephrine                 4603 pg/mL       \<149 pg/mL
  Total metanephrine              4862 pg/mL       \<206 pg/mL
  Epinephrine                     16 pg/mL         \<84 pg/mL
  Norepinephrine                  509 pg/mL        \<420 pg/mL
  Dopamine                        \<30 pg/mL       \<60 pg/mL
  Total catecholamines            525 pg/mL        \<504 pg/mL
  *Test (24-hour urine values)*                     
  Total catecholamines            131 ug/24 hr     \<100 ug/24 hr
  Norepinephrine                  120 ug/24 hr     \<80 ug/24 hr
  Epinephrine                     11 ug/24 hr      \<20 ug/24 hr
  Dopamine                        466 ug/24 hr     \<500 ug/24 hr
  Vanillylmandelate (VMA)         88.3 ug/24 hr    3.8--6.7 mg/24 hr
  Creatinine                      1.47 ug/24 hr    0.63--2.50 g/24 hr

###### 

A summary of reported giant pheochromocytomas with maximal diameter greater than 10 cm, arranged by largest to smallest maximum diameter. The weight was not recorded in many of the papers.

  Author/year                                Sex/age   Country             Size (cm)/weight (g)   Location                     Presentation                                     Histopathological evaluation   Metastasis
  ------------------------------------------ --------- ------------------- ---------------------- ---------------------------- ------------------------------------------------ ------------------------------ -----------------
  Grissom et al./1979 \[[@B15]\]             F/54      USA                 45 × 25/3000+          Left abdomen                 Asymptomatic                                     Unknown                        None
  Costa et al./2008 \[[@B5]\]                M/46      Brazil              30/unknown             Right adrenal                Abdominal pain                                   Malignant                      Liver
  Basso et al./1996 \[[@B16]\]               M/47      Italy               29 × 21 × 12/4050      Left abdomen                 Asymptomatic                                     Malignant                      None
  Karumanchery et al./2012 \[[@B17]\]        F/85      England             28 × 16 × 13/2300      Left abdomen                 Lower back pain                                  Unknown                        None
  Current case                               F/50      Trinidad & Tobago   27 × 18 × 12/3315      Left abdomen                 Lower back pain                                  Low risk of malignancy         None
  Gupta et al./2016 \[[@B18]\]               F/65      India               25 × 17 × 15/2750      Left abdomen                 Asymptomatic                                     Benign                         None
  Okuda et al./2013 \[[@B19]\]               F/43      Japan               24 × 23 × 16/5900      Abdomen                      Vulva edema                                      Unknown                        None
  Suga et al./2000 \[[@B20]\]                M/48      Japan               21 × 13 × 21/3900      Left abdomen                 Asymptomatic                                     Unknown                        None
  Terk et al./1993 \[[@B21]\]                M/35      USA                 21 × 20 × 11/2870      Organ of Zuckerkandl         Disproportionate abdominal girth, hypertension   Unknown                        None
  Soufi et al./2012 \[[@B11]\]               F/17      India               21 × 15                Right upper abdomen          Asymptomatic                                     Malignant                      None
  Arcos et al./2009 \[[@B22]\]               F/36      Canada              21 × 17 × 11           Left abdomen                 Lower back pain                                  Malignant                      Lymph node
  Melegh et al./2002 \[[@B23]\]              M/55      Hungary             20/unknown             Left renal hilus             Asymptomatic                                     Unknown                        None
  Korgali et al./2014 \[[@B24]\]             M/63      Turkey              20 × 17 × 9/1736       Left adrenal gland           Chest pain, sweating, nausea                     Malignant                      Rib
  Ambati et al./2014 \[[@B12]\]              F/77      Canada              19 × 18 × 12/2460      Right retroperitoneum        Dyspnea                                          Benign                         None
  Pan et al./2008 \[[@B25]\]                 M/46      USA                 18 × 14 × 13/1450      Left abdomen                 Episodic hypertension and headache               Unknown                        Unknown
  Uysal et al./2015 \[[@B26]\]               M/37      Turkey              18 × 8 × 13            Left abdomen                 Hypertension                                     Malignant                      Multiorgan^*∗*^
  Sharma/2006 \[[@B27]\]                     M/55      India               17 × 12/850            Right adrenal gland          Asymptomatic                                     Benign                         None
  Daughtry et al./1977 \[[@B28]\]            M/53      USA                 17/1150                Unknown                      Mild hypertension                                Unknown                        Unknown
  Gupta et al./2016 \[[@B18]\]               M/40      India               16.4 × 14 /1836        Left thyroid gland           Severe hypertension                              Unknown                        Unknown
  Costa et al./2008 \[[@B5]\]                F/43      Brazil              16                     Right upper abdomen          Abdominal pain                                   Malignant                      Unknown
  Jain and Agarwal /2002 \[[@B29]\]          F/26      India               16 × 11                Left abdomen                 Asymptomatic                                     Malignant                      Unknown
  Wu et al./2000 \[[@B30]\]                  F/49      USA                 15 × 12 × 12           Right upper abdomen          Asymptomatic                                     Unknown                        Unknown
  Santarone et al./2008 \[[@B31]\]           F/81      Italy               13                     Right upper abdomen          Hypertension, palpitation, sweating              Unknown                        Unknown
  Sundahl et al./2016 \[[@B32]\]             F/54      Sweden              12.5 × 10 × 3/204      Right adrenal gland          Asymptomatic                                     Benign                         None
  Zhu et al./2014 \[[@B33]\]                 F/67      Japan               12.1 × 10.8            Left adrenal gland           Dizziness, vomiting, and stomachache             Unknown                        None
  Ikegami et al./2009 \[[@B34]\]             M/47      Japan               12 × 10                Abdomen                      Back pain                                        Unknown                        Unknown
  Li et al./2012 \[[@B35]\]                  M/56      Canada              12 × 11 × 11           Right upper abdomen          Progressive weight loss and nausea               Benign                         None
  Kakoki et al./2015 \[[@B36]\]              M/70      Japan               12 × 11 × 8/530        Left adrenal gland           Ileus after hypertension medication              Benign                         None
  Schnakenburg et al./1976 \[[@B37]\]        M/12      Ukraine             12 × 10 × 9/1100       Right abdomen                Hemihypertrophy                                  Malignant                      Lung, brain
  Filippou et al./2003 \[[@B38]\]            M/70      Greece              12 × 8 × 10            Left abdomen                 Asymptomatic                                     Malignant                      None
  Sarveswaran et al./2015 \[[@B39]\]         F/59      India               11.2 × 9.6 × 9.8       Right suprarenal region      Upper right abdominal discomfort                 Unknown                        Unknown
  Chan et al./2000 \[[@B40]\]                M/63      China               11 × 6.6 × 11          Right suprarenal region      Asymptomatic                                     Malignant                      Bone, lung
  Awada et al./2003 \[[@B41]\]               F/26      USA                 11 × 10 × 9            Right adrenal gland          Dyspnea, paresthesia, chest pain, palpitation    Unknown                        Unknown
  Goldberg et al./2011 \[[@B42]\]            F/27      Canada              10.5 × 10.6            Right adrenal gland region   Headaches, episodic palpitations, pallor         Unknown                        Unknown
  Antedomenico and Wascher/2005 \[[@B43]\]   F/39      USA                 10.5/782               Left upper abdomen           Abdominal pain                                   Unknown                        Unknown
  Wang et al./2015 \[[@B13]\]                F/36      China               10.3 × 9.3             Left upper abdomen           Abdominal pain                                   Unknown                        Unknown
  Basiri and Radfar/2010 \[[@B44]\]          M/53      Iran                Unknown/3150           Left abdomen                 Abdominal pain                                   Benign                         None

M, male; F, female. ^*∗*^Liver, lymph nodes, right adrenal gland, lungs, and bones.
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